Magnesium sulfate in prevention of vancomycin+piperacillin-tazobactam nephrotoxicity
Phase 2
Recruiting
- Conditions
- Acute Kidney Injury.Acute renal failure with tubular necrosisN17.0
- Registration Number
- IRCT20100228003449N26
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 54
Inclusion Criteria
Patients with age between 18-75 years
Patients without history of renal failure
Patients with indication to receive vancomycin+piperacillin-tazobactam
Exclusion Criteria
known history of hypersensitivity reactions to vancomycin and betalactams
Pregnancy
Patients with creatinine clearance less than 60 ml/min
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of acute kidney injury. Timepoint: Daily. Method of measurement: Increase in serum creatinine by 0.3 mg/dl or more than 50% from the baseline value.;Time of acute kidney injury occurrence. Timepoint: Daily. Method of measurement: Recording of incidence time.
- Secondary Outcome Measures
Name Time Method ength of ICU stay. Timepoint: Daily. Method of measurement: Recording of stay days.